Imidazo[1,2- a ]Pyridine Derivatives as Novel Dual-Target Inhibitors of ABCB1 and ABCG2 for Reversing Multidrug Resistance
Journal of Medicinal Chemistry · 23.02.2023 · 66 (4) · 2804-2831
DOI: 10.1021/acs.jmedchem.2c01862 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 13.02.2023. Verfasst von Hui Li und 13 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, and Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 2100…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Drug Resistance, Multiple, Drug Resistance, Neoplasm, ATP Binding Cassette Transporter, Subfamily B, Member 2. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: State Key Laboratory of Natural Medicines, Qinglan Project of Jiangsu Province of China, China Pharmaceutical University.
Abstract (Originalsprache)
ABCB1 and ABCG2 are the important ATP-binding cassette (ABC) transporters associated with multidrug resistance (MDR). Herein, we designed a series of imidazo[1,2-a]pyridine derivatives as dual-target inhibitors of ABCB1 and ABCG2 through the scaffold hopping strategy. Compound Y22 displayed potential efflux function inhibitory toward both ABCB1 and ABCG2 (reversal fold: ABCB1 = 8.35 and ABCG2 = 2.71) without obvious cytotoxicity. Y22 also enhanced the potency of antiproliferative drugs in vitro. Mechanistic studies demonstrated that Y22 slightly suppressed ATPase activity but did not affect the protein expression of ABCB1 or ABCG2. Notably, Y22 exhibited negligible CYP3A4 inhibition and enhanced the antiproliferative activity of adriamycin in vivo by restoring the sensitivity of resistant cells. Thus, Y22 may be effective clinically in combination with common chemotherapy agents. In summary, Y22 is a potential dual-target inhibitor that reverses MDR by blocking the efflux function of ABCB1 and ABCG2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural Medicines, and Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
- Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
- Department of Operational Medicine, Tianjin Institute of Environmental & Operational Medicine, Tianjin 300050, China.
ORCID-Profile: Qi-Dong You, Xiao-Li Xu
Förderung
- State Key Laboratory of Natural Medicines
- Qinglan Project of Jiangsu Province of China
- China Pharmaceutical University
- National Natural Science Foundation of China
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- Foundation Research Project of Jiangsu Province
Zitieren
APA
Li, H., Zhang, S. L., Jia, Y. H., Li, Q., Feng, Z. W., Zhang, S. D., Zheng, W., Zhou, Y. L., Li, L. L., Liu, X. C., Chen, Y. Q., Peng, H., You, Q. D., & Xu, X. L. (2023). Imidazo[1,2- a ]Pyridine Derivatives as Novel Dual-Target Inhibitors of ABCB1 and ABCG2 for Reversing Multidrug Resistance. Journal of Medicinal Chemistry, 66(4), 2804-2831. https://doi.org/10.1021/acs.jmedchem.2c01862
Vancouver
Li H, Zhang SL, Jia YH, Li Q, Feng ZW, Zhang SD, et al. Imidazo[1,2- a ]Pyridine Derivatives as Novel Dual-Target Inhibitors of ABCB1 and ABCG2 for Reversing Multidrug Resistance. Journal of Medicinal Chemistry. 2023;66(4):2804-2831. doi:10.1021/acs.jmedchem.2c01862
BibTeX
@article{Li2023,
author = {Li, Hui and Zhang, Sheng-Lie and Jia, Yan-Han and Li, Qian and Feng, Zi-Wen and Zhang, Shi-Duo and Zheng, Wei and Zhou, Ye-Ling and Li, Lin-Lin and Liu, Xue-Chun and Chen, Ya-Qiong and Peng, Hui and You, Qi-Dong and Xu, Xiao-Li},
title = {Imidazo[1,2- a ]Pyridine Derivatives as Novel Dual-Target Inhibitors of ABCB1 and ABCG2 for Reversing Multidrug Resistance},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {4},
pages = {2804--2831},
doi = {10.1021/acs.jmedchem.2c01862}
}
EUVIMED